In a recent study posted to bioRxiv*, researchers at Washington University School of Medicine, St. Louis, demonstrated that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine booster elicits robust germinal center (GC) B cell responses.